To review human data on the efficacy, safety, and clinical use of trivalent intranasal influenza vaccine, live (TIIVL).
DATA SOURCES
A MEDLINE search (1966–3rd week of January 2004) using the terms influenza vaccine, intranasal administration, and FluMist was conducted. References from pertinent articles were also reviewed.
STUDY SELECTION AND DATA EXTRACTION
Studies conducted in humans and published in English were selected. Double-blind, controlled trials evaluating the efficacy and safety of TIIVL were evaluated.
DATA SYNTHESIS
Administration of TIIVL results in mucosal and humoral immunity to influenza. Results of clinical trials in children and adults have demonstrated that TIIVL reduces the incidence of influenza. In children, TIIVL was also associated with a decrease in febrile illness and febrile otitis media. In adults, reductions in workday absences and medical visits due to febrile upper respiratory tract illness were also documented. TIIVL is well tolerated, with rhinorrhea or nasal congestion and sore throat occurring more frequently than with placebo.
CONCLUSIONS
TIIVL is an alternative to intramuscular inactivated influenza vaccine in healthy individuals between 5 and 49 years of age. However, the vaccine is contraindicated in the majority of patient populations for whom annual influenza vaccination is recommended.
THIS ARTICLE IS APPROVED FOR CONTINUING EDUCATION CREDIT
. ThompsonWW, ShayDK, WeintraubE, BrammerL, CoxN, AndersonLJ, Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA2003; 289: 179–86.
2.
. DolanS, NyquistAC, OndrejkaD, ToddJ, GershmanK, AlexanderJ, Preliminary assessment of the effectiveness of the 2003–04 inactivated influenza vaccine—Colorado, December 2003. MMWR Morb Mortal Wkly Rep2004; 53: 8–11.
3.
. HarperSA, FukudaK, UyekiTM, CoxNJ, BridgesCB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices. MMWR Morb Mortal Wkly Rep2004; 53 (RR06): 1–40.
4.
. JacobsonRM, PolandGA. Universal vaccination of healthy children against influenza: a role for the cold-adapted intranasal influenza vaccine. Pediatr Drugs2002; 4: 66–71.
5.
. PiedraPA. Safety of the trivalent, cold-adapted influenza vaccine (CAIV-T) in children. Semin Pediatr Infect Dis2002; 13: 90–6.
. CoxRJ, BrokstadKA, OgraP. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol2004; 59: 1–15.
14.
. BryantML, BrownP, GurevichN, McDougallIR. Comparison of the clearance of radiolabeled nose drops and nasal spray as a mucosally delivered vaccine. Nucl Med Comm1999; 20; 171–4.
15.
. MendelmanPM, CordovaJ, ChoI. Safety, efficacy and effectiveness of the influenza virus vaccine, trivalent, types A and B, live, cold-adapted (CAIV-T) in healthy children and healthy adults. Vaccine2001; 19: 2221–6.
16.
. BelsheRB, MendelmanPM, TreanorJ, KingJ, GruberW, PiedraP, The efficacy of live attenuated, cold adapted, trivalent intranasal influenza virus vaccine in children. N Engl J Med1998; 338: 1405–12.
17.
. BelsheRB, GruberWC, MendelmanPM, ChoI, ReisingerK, BlockSL, Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr2000; 136: 168–75.
18.
. BelsheRB, GruberWC. Prevention of otitis media in children with live attenuated influenza vaccine given intranasally. Pediatr Infect Dis J2000; 19 (5 suppl): S66–71.
19.
. NicholKL, MendelmanPM, MallonKP, JacksonLA, GorseGJ, BelsheRB, Effectiveness of live, attenuated intranasal vaccine in healthy, working adults. JAMA1999; 282: 137–44.
20.
. TreanorJJ, KotloffK, BettesRF, BelsheR, NewmanF, IacuzioD, Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine2000; 18: 899–906.
21.
. EdwardsKM, Dupont WD WestrichMK, PlummerWDJ, PalmerPS, WrightPF. A randomized controlled trial of cold adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis1994; 169: 68–76.
22.
. ClementsML, BettsRF, MurphyBR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet1984; 1: 704–8.
23.
. ClementsML, BettsRF, TierneyEL, MurphyBR. Resistance of adults to challenge with influenza A wild-type virus after receiving live or inactivated virus vaccine. J Clin Microbiol1986; 23: 73–6.
24.
. TreanorJJ, RothFK, BettsRF. Use of live cold-adapted influenza A H1N1 and H3N2 virus vaccines in seropositive adults. J Clin Microbiol1990; 28: 596–9.
25.
. ClementsML, SnyderMH, SearsSD, MaassabHF, MurphyBR. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/1/86 reassortant virus in adult volunteers. J Infect Dis1990; 161: 869–77.
26.
. BergenR, BlackS, ShinefieldH, LewisE, RayR, HansenJ, Safety of cold-adapted live attenuated influenza vaccine in a large cohort of children and adolescents. Pediatr Infect Dis J2004; 23: 138–44.
27.
. AliT, ScottN, KallasW, HalliwellME, SavinoC, RosenberE, Detection of influenza antigen with rapid antibody-based tests after intranasal influenza vaccination (FluMist). Clin Infect Dis2004; 38: 760–2.
28.
. ReddingG, WalkerRE, HesselC, VirantFS, AyarsGH, BenschG, Safety and tolerability of cold-adapted influenza virus vaccine in children and adolescents with asthma. Pediatr Infect Dis J2002; 21: 44–8.
29.
. GorseGJ, O'ConnorTZ, YoungSL, MendelmanPM, BradleySF, NicholKL, Efficacy trial of live, cold-adapted and inactivated influenza virus vaccines in older adults with chronic obstructive pulmonary disease: a VA cooperative study. Vaccine2003; 21: 2133–44.
30.
. KingJC, FastPE, ZangwillKM, WeinbergGA, WolffM, YanL, Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus–infected and noninfected children. Pediatr Infect Dis J2001; 20: 1124–31.
31.
. KingJC, TreanorJ, FastPE, WolffM, YanL, IacuzioD, Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)–infected and non–HIV-infected adults. J Infect Dis2000; 181: 725–8.
32.
. Influenza prevention 2003–2004. Med Lett Drugs Ther2003; 45: 78–80.
. 2003 Drug topics red book. Montvale, NJ: Thomson PDR, 2003.
35.
. NicholKL, MallonKP, MendelmanPM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine2003; 21: 2207–17.
36.
. LuceBR, ZangwillKM, PalmerCS, MendelmanPM, YanL, WolffMC, Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics2001; 108 (2): e24. http://pediatrics.aappublications.org/cgi/content/full/108/2/e24 (accessed 2004 Sept 16).
37.
. Dear health care professional letter. Gaithersburg, MD: MedImmune, December 31, 2003.
38.
. Vaccine information statement (VIS) for live, intranasal influenza vaccine. Department of Health and Human Services. Atlanta: Centers for Disease Control and Prevention. www.cdc.gov/nip/publications/VIS/vis-flulive.pdf (accessed 2004 Sept 29).
